A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.

Trial Details

NCT ID
NCT06590246
Phase
PHASE1 / PHASE2
Sponsor
Shanghai AbelZeta Ltd.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Armored and GPC3-targeted autologous CAR T-cell
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Hanzhou, Zhejiang, China

Key Eligibility Criteria

  • The participant voluntarily participates in the study, and the individual or their legal guardian signs the informed consent form (ICF).
  • 18 \~ 75 years of age at the time of signing ICF.
  • Clinical trial participants with advanced HCC confirmed by histopathological or cytological examination with the following requirements (no mixed H…
  • Barcelona Clinic Liver Cancer (BCLC) stage C or B (not amenable to surgery/local treatment, includes ablative therapy, interventional and radiation…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →